Exagen Inc. to Participate in the Canaccord Genuity 42nd Annual Growth Conference
July 25 2022 - 4:05PM
Exagen Inc. (Nasdaq: XGN), a leading provider of
autoimmune testing solutions, today announced its participation in
the Canaccord Genuity 42nd Annual Growth Conference, which takes
place August 8-11, 2022, in Boston at the InterContinental Boston
Hotel. Ron Rocca, Exagen’s President and Chief Executive Officer,
and Kamal Adawi, Exagen’s Chief Financial Officer, will present on
Thursday, August 11th, at 12:00 PM ET. Interested parties may
access the webcast of the presentation using a link on Exagen’s
website at https://investors.exagen.com/events.
About Exagen Inc.
Exagen (Nasdaq: XGN) is a leading provider
of autoimmune diagnostic, prognostic, and monitoring testing
solutions. Exagen is a patient focused, discovery driven
organization built on the success of AVISE testing and is investing
in its product pipeline to support patients throughout their
autoimmune diagnosis and treatment journeys. The goal at Exagen is
to assist patients, physicians, and payors by enabling precision
medicine. Exagen is located in San Diego
County with clinical and research and development laboratories
in Vista, CA.
For more information, please
visit Exagen.com and follow @ExagenInc on
Twitter.
Forward Looking Statements
Exagen cautions you that statements contained in
this press release regarding matters that are not historical facts
are forward-looking statements. These statements are based on
Exagen's current beliefs and expectations. The inclusion of
forward-looking statements should not be regarded as a
representation by Exagen that any of its plans will be achieved.
Actual results may differ from those set forth in this press
release due to the risks and uncertainties inherent in Exagen’s
business, including, without limitation: the COVID-19 pandemic may
continue to adversely affect its business, financial condition and
results of operations, including as a result of slowdown in its
operations as well as those of its suppliers and courier services,
impeding patient movement and interruptions to healthcare services
causing a decrease in test volumes, disruptions to the supply chain
of material needed for its tests causing an increase in cost per
test, its sales and commercialization activities and its ability to
receive specimens and perform or deliver the results from its
tests, delays in reimbursement and coverage decisions from Medicare
and third-party payors and in interactions with regulatory
authorities, and delays in ongoing and planned clinical trials
involving its tests; Exagen’s commercial success depends upon
attaining and maintaining significant market acceptance of its
testing products and promoted therapeutics among rheumatologists,
patients, third-party payors and others in the medical community;
Exagen’s ability to successfully execute on its business
strategies; third party payors not providing coverage and adequate
reimbursement for Exagen’s testing products or promoted
therapeutics, including Exagen’s ability to collect on funds due;
Exagen’s ability to obtain and maintain intellectual property
protection for its testing products; regulatory developments
affecting Exagen’s business; and other risks described in Exagen’s
prior press releases and Exagen’s filings with the Securities and
Exchange Commission (“SEC”), including under the heading “Risk
Factors” in Exagen’s Annual Report on Form 10-K for the year ended
December 31, 2021 and any subsequent filings with the SEC. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and Exagen
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date
hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement, which is made under the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995.
Investor RelationsExagen Inc.
Ryan Douglasrdouglas@exagen.com 760.560.1525
CompanyExagen Inc.Kamal Adawi,
Chief Financial Officerkadawi@exagen.com 760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Sep 2023 to Sep 2024